CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

The difference between CJC 1295 with DAC and CJC 1295 without DAC comes down to one thing: how long the compound stays active in your blood, and what that extended presence actually does to the system you are trying to improve.

To understand why that matters, you need the full picture first.

Your pituitary gland releases growth hormone in pulses, not as a steady stream, and those pulses are driven by something called GHRH, which is growth hormone releasing hormone, the signal your hypothalamus sends to tell the pituitary to fire. Between those pulses there are valleys, periods where growth hormone levels drop back down near baseline, and those valleys are not wasted time. They are part of how the system works. The pulse and the valley together create what is called a pulsatile rhythm, and that rhythm is what drives the downstream effects you are after, including fat breakdown and body composition changes.

CJC 1295 without DAC is a synthetic version of GHRH that mimics that natural signal. It has a half life of about 30 minutes, so you inject it, it amplifies the next growth hormone pulse from your pituitary, and then it clears. Your natural pulses keep firing between doses on their own schedule, so the valleys stay intact and your body's rhythm is preserved. You are essentially adding signal on top of a working system.

Then there is CJC 1295 with DAC, where DAC stands for drug affinity complex, which is a modification that allows the peptide to bind to albumin, a protein already circulating in your blood, and use it as a kind of slow-release reservoir. That single modification extends the half life from 30 minutes to somewhere between 5.8 and 8.1 days depending on the individual. One injection and the compound is still active a week later.

That sounds like a straightforward upgrade. Fewer injections, same effect. But that is not what the data shows.

A 2006 study by Ionescu and Frohman looked directly at what CJC 1295 with DAC does to growth hormone patterns in humans. The pituitary kept pulsing, which on the surface sounds fine, but the trough levels between those pulses, the valleys, were elevated 7.5 times above normal. The pulses were still there, but they were now sitting on top of a chronically elevated baseline rather than returning to a true low between each one. The rhythm was technically intact but the pattern had shifted from peaks and valleys to peaks on top of a plateau.

That shift is the whole problem.

A study by Surya and colleagues tested whether that distinction actually matters for outcomes. They compared pulsatile growth hormone delivery against continuous growth hormone delivery in obese human subjects and measured lipolysis, which is the process of breaking fat down for use as fuel. The pulsatile group saw fat breakdown nearly double, going from a baseline of 4.1 up to 7.1. The continuous group went from 4.1 to 4.8, a change that was not statistically different from doing nothing at all.

Same hormone, same dose, completely different results based on delivery pattern alone.

The reason that happens has to do with receptor behavior. When a receptor gets exposed to the same signal continuously rather than in pulses, it starts to pull back its own sensitivity in a process called downregulation, which is essentially the cell reducing its response to a signal it is seeing too much of. A 1997 study by Aleppo and colleagues found that just four hours of continuous GHRH exposure was enough to reduce GHRH receptor messenger RNA, the instructions the cell uses to build those receptors, down to 49 to 54 percent of baseline. The reduction was dose dependent and driven by a signaling molecule called cAMP. The longer and more continuously the signal runs, the fewer receptors are available to respond to it.

DAC does not cause four hours of continuous exposure. It causes roughly a week of it. So the mechanism that produces downregulation is not just present, it is running at full strength for the entire duration of the compound's activity.

This is why the valleys matter. They are the recovery period that keeps the receptors sensitive to the next pulse. Remove the valleys and you remove the mechanism that makes pulsatile delivery work.

The practical question from all of this is simple. If you are choosing a secretagogue because you want to work with your body's natural growth hormone system rather than override it, CJC 1295 without DAC is the version that actually does that. It amplifies the signal and then clears, so the architecture of the system stays functional between doses.

If you are considering CJC 1295 with DAC because you want to minimize injection frequency, it is worth understanding what you are trading for that convenience. You are moving away from pulsatile delivery toward something that looks a lot more like continuous elevation, which is the exact pattern that the evidence shows produces no meaningful fat loss benefit.

And if continuous elevation is acceptable to you, actual growth hormone accomplishes that more precisely, with a known dose and decades of clinical data behind it. DAC leaves you between two approaches without the defining advantage of either one.

The reason secretagogues exist as a category is that they preserve something growth hormone replacement does not, which is the pulsatile pattern your body already uses. The version of CJC 1295 that actually preserves it is the one without the albumin binding modification.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness